Progress and perspectives in chemoprevention of head and neck cancer

References

• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer 1 Clin. 53(1), 5–26 (2003).
   Google Scholar
• Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 18(6B), 4779–4786 (1998).
   Google Scholar
• American Cancer Society, Surveillance Research. Cancer facts and figures. American Cancer Society, GA, USA, 1–41 (2001).
   Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371–1388 (1998).
   Google Scholar
• Cummings SR, Eckert S, Krueger IKA et al The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAIVIA 281(23), 2189–2197 (1999).
   PubMed Web of Science ®Google Scholar
• Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. j Natl Cancer Inst. 91(21), 1847–1856 (1999).
   Google Scholar
• Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin. Cancer Res. 7(12 Suppl.), 4413s-4418s (2001).
   Google Scholar
• Steinbach G, Lynch PM, Phillips RIK et al The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. J. Merl 342 (26), 1946-1952 (2000).
   Google Scholar
• Peto R, Doll R, Buckley JD, Sporn MB. Can dietary I3-carotene materially reduce human cancer rates? Nature 290(5803), 201–208 (1981).
   Google Scholar
• National Research Council. Diet, nutrition and cancer National Academy Press, WA, USA (1982).
   Google Scholar
• Greenwald P NCI cancer prevention and control research. Prey. Merl 22(5), 642–660 (1993).
   Google Scholar
• Lippman SM, Benner SE, Hong WK. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. Cancer Res. 54(7 Suppl.), 2025s-2028s (1994).
   Google Scholar
• The a-Tocopherol, 0-Carotene Cancer Prevention Study Group.The effect of vitamin E and I3-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med 330(15), 1029–1035 (1994).
   Google Scholar
• Omenn GS, Goodman GE, Thornquist MD et al Effects of a combination of I3-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl. J. Merl 334(18), 1150–1155 (1996).
   Google Scholar
• Hennekens CH, Buring JE, Manson JE et al Lack of effect of long-term supplementation with I3-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl. I Merl 334(18), 1145–1149 (1996).
   Google Scholar
• Lippman SM, Lee JJ, Karp DD et al Randomized Phase III Intergroup trial of isotretinoin to prevent second primary tumors in Stage I non-small-cell lung cancer. 1 Natl Cancer Inst. 93(8), 605–618 (2001).
   Google Scholar
• Omenn GS, Goodman GE, Thornquist MD et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J. Natl Cancer Inst. 88(21), 1550–1559 (1996).
   PubMedGoogle Scholar
• Hong WK, Endicott J, Itri LM et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med 315 (24), 1501–1505 (1986).
   Google Scholar
• •Phase III study comparing 13-cis-retinoic acid with placebo in subjects with oral leukoplakia, demonstrating clinical and histologic improvement with 13-cis-retinoic acid, however, rates of toxicities were high.
   Google Scholar
• Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl. J. Merl 323(12), 795–801 (1990).
   Google Scholar
• •Phase III study comparing 13-cis-retinoic acid with placebo for second primary tumor prevention in subjects with head and neck squamous cell carcinoma (HNSCC). The 13-cis-retinoic acid group experienced significantly fewer second cancers, however toxicities were again high.
   Google Scholar
• Slaughter DL, Southwick HW, Smejkal W. 'Field cancerization' in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6,963 (1953).
   Google Scholar
• Califano J, van der Riet P, Westra W et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56(11), 2488–2492 (1996).
   Google Scholar
• Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res. 56(11), 2484–2487 (1996).
   PubMed Web of Science ®Google Scholar
• Scholes AG, Woolgar JA, Boyle MA et al Synchronous oral carcinomas: independent or common clonal origin? Cancer Res. 58(9), 2003–2006 (1998).
   Google Scholar
• Tabor MP, Brakenhoff RH, van Houten VM et al Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 7(6), 1523–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Brennan JA, Mao L, Hruban RII et al Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl. J. Merl 332(7), 429–435 (1995).
   Google Scholar
• Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RII. A geneticexplanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63 (8), 1727–1730 (2003).
   PubMed Web of Science ®Google Scholar
• ••Presents a thought-provoking review ofgenetic events underlying field cancerization and propose a reformulation of the concept of field cancerization, with important clinical implications.
   Google Scholar
• Mao L, Lee JS, Fan YH et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Merl 2(6), 682–685 (1996).
   Google Scholar
• Reed AL, Califano J, Cairns P et al High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56(16), 3630–3633 (1996).
   Google Scholar
• Papadimitrakopoulou V, Izzo J, Lippman SM et al Frequent inactivation of pl6INK4a in oral premalignant lesions. Oncogene 14(15), 1799–1803 (1997).
   Google Scholar
• El-Naggar AK, Lai S, Clayman G et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am. J. Athol 151(6), 1767–1774 (1997).
   Google Scholar
• Sanchez-Cespedes M, Esteller M, Wu L et al Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60(4), 892–895 (2000).
   Google Scholar
• Rosas SL, Koch W, da Costa Carvalho MG et al. Promoter hypermethylation patterns of p16, 06-methylguanine-DNA-methyltransferase and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61(3), 939–942 (2001).
   Google Scholar
• Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21(27), 4231–4236 (2002).
   PubMed Web of Science ®Google Scholar
• Jares P, Fernandez PL, Campo E et al PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res. 54(17), 4813–4817 (1994).
   Google Scholar
• Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 55(5), 975–978 (1995).
   Google Scholar
• Izzo JG, Papadimitrakopoulou VA, Li XQ et al Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 17(18), 2313–2322 (1998).
   Google Scholar
• Okami K, Reed AL, Cairns P et al Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 18(23), 3541–3545 (1999).
   Google Scholar
• Papadimitrakopoulou VA, Izzo J, Mao L et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin. Cancer Res. 7(10), 3127–3134 (2001).
   Google Scholar
• Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res. 52 (21), 5997–6000 (1992).
   Google Scholar
• Boyle JO, Hakim J, Koch W et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53(19), 4477–4480 (1993).
   Google Scholar
• Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum. Pathol 30 (10), 1221–1225 (1999).
   Google Scholar
• Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. j Oral Pathol Merl 29(9), 413–425 (2000).
   Google Scholar
• Shin DM, Charuruks N, Lippman SM et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarker s Pmv. 10(6), 603–609 (2001).
   Google Scholar
• Brennan JA, Boyle JO, Koch WM et al Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl. Merl 332(11), 712–717 (1995).
   Google Scholar
• Koch WM, Brennan JA, Zahurak M et al P53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. j Natl Cancer Inst. 88 (21), 1580–1586 (1996).
   Google Scholar
• Shin DM, Lee JS, Lippman SM et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. j Natl Cancer Inst. 88(8), 519–529 (1996).
   Google Scholar
• Geisler SA, Olshan AF, Weissler MC et al p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin. Cancer Res. 8(11), 3445–3453 (2002).
   Google Scholar
• Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6(2), 347–352 (2000).
   Google Scholar
• Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancers. Ann. Rev Merl 53,223–243 (2002).
   PubMedGoogle Scholar
• Zhang L, Poh CF, Lam WL et al Impact of localized treatment in reducing risk of progression of low- grade oral dysplasia: molecular evidence of incomplete resection. Oial °Tirol 37(6), 505–512 (2001).
   Google Scholar
• Jiang WW, Fujii H, Shirai T, Mega H, Takagi M. Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer 92(9), 2349–2356 (2001).
   Google Scholar
• Papadimitrakopoulou VA, Liu DD, Mao L et al Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epiclemiol Biomarkers. Prey. 11(12), 1605–1610 (2002).
   Google Scholar
• Sudbo J, Kildal W, Risberg B, Koppang H, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl. I Merl 344 (17), 1270–1278 (2001).
   Google Scholar
• •Demonstrated that abnormal DNA content is highly predictive of future invasive HNSCC in subjects with oral leukoplakia.
   Google Scholar
• Sudbo J, Kildal W Johannessen AC et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. j Clin. Oncol 20(2), 456–462 (2002).
   Google Scholar
• Opitz OG, Harada H, Suliman Y et al A mouse model of human oral-esophageal cancer.J Clin. Invest. 110(6), 761–769 (2002).
   Google Scholar
• Maser RS, DePinho RA. Connecting chromosomes, crisis and cancer. Science 297(5581), 565–569 (2002).
   Google Scholar
• McCaul JA, Gordon KE, Clark LJ, Parkinson EK. Telomerase inhibition and the future management of head and neck cancer. Lancet Oncol 3(5), 280–288 (2002).
   Google Scholar
• Kannan S, Tahara H, Yokozaki H et al. Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epiclemiol Biomarkers. Prey. 6(6), 413–420 (1997).
   Google Scholar
• Mao L, El-Naggar AK, Fan YH et al Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 56(24), 5600–5604 (1996).
   Google Scholar
• Downey MG, Going JJ, Stuart RC, Keith WN. Expression of telomerase RNA in oesophageal and oral cancer. j Oral Pathol Merl 30(10), 577–581 (2001).
   Google Scholar
• XU XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant and malignant head and neck tissues. Cancer Res. 54(13), 3580–3587 (1994).
   Google Scholar
• X11 XC, Zile MET, Lippman SM et al Antiretinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor-I3 expression. Cancer Res. 55(23), 5507–5511 (1995).
   Google Scholar
• Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Grit. Rev. Oncol Hematol 41(1), 41–55 (2002).
   Google Scholar
• Todd R, Wong DT Epidermal growth factor receptor (EGFR) biology and human oral cancer. Ifistol Histopathol 14(2), 491–500 (1999).
   Google Scholar
• Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25 (1), 67–73 (2003) .
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor-a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53(15), 3579–3584 (1993).
   Google Scholar
• Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54 (12), 3153–3159 (1994).
   PubMed Web of Science ®Google Scholar
• Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-a and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78(6), 1284–1292 (1996).
   Google Scholar
• Uhlman DL, Adams G, Knapp D, Aeppli DM, Niehans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res. 56(9), 2199–2205 (1996).
   Google Scholar
• Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor-a and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin. Cancer Res. 4(1), 13–20 (1998).
   Google Scholar
• Grandis JR, Melhem MF, Gooding WE et al Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. j Natl Cancer Inst. 90(11), 824–832 (1998).
   Google Scholar
• Dassonville 0, Formento JL, Francoual M et al Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. j Clin. Oncol 11(10), 1873–1878 (1993).
   Google Scholar
• Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Bkoc/76(4), 655–663 (1990).
   Google Scholar
• Chen Z, Malhotra PS, Thomas GR et al. Expression of pro-inflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 5(6), 1369–1379 (1999).
   PubMed Web of Science ®Google Scholar
• Hong SH, Ondrey FG, Avis IM et al Cyclooxygenase regulates human oropharyngeal carcinomas via the pro-inflammatory cytokine 11-6: a general role for inflammation? FASEB14,1499–1507 (2000).
   PubMedGoogle Scholar
• Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24(8), 792–799 (2002).
   Google Scholar
• Moraitis D, Almahmeed T, Weksler B et al. Tobacco smoke induces cyclo-oxygenase-2 in epithelial cell lines derived from the human aerodigestive tract. AACR Abstracts 43,349 (2002).
   Google Scholar
• Wiese FW, Thompson PA, Kadlubar FE Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 22(1), 5–10 (2001).
   Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (6398), 843–845 (1992).
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hon i M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Ce1193(5), 705–716 (1998).
   Google Scholar
• Gallo 0, Masini E, Bianchi B et al. Correlation between cyclooxygenase-2 pathways and tumor angiogenesis in head and neck cancer and its prognosistic significance. Neoplasia 3,53–66 (2000).
   Google Scholar
• Seno H, Oshima M, Ishikawa TO et al. Cyclooxygenase-2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62(2), 506–511 (2002).
   Google Scholar
• Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62(3), 625–631 (2002).
   Google Scholar
• Huang M, Stolina M, Sharma S et al Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin-10 and downregulation of interleukin-12 production. Cancer Res. 58 (6), 1208–1216 (1998).
   Google Scholar
• Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod. Pathol 10(11), 1128–1133 (1997).
   Google Scholar
• Masferrer JL, Leahy KM, Koki AT et al Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60(5), 1306–1311 (2000).
   Google Scholar
• Mineta H, Miura K, Ogino T et al Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. BE J. Cancer 83(6), 775–781 (2000).
   Google Scholar
• Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. j Clin. Oncol 18(10), 2046-2052 (2000).
   Google Scholar
• Tae K, El-Naggar AK, Yoo E et al Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin. Cancer Res. 6(7), 2821–2828 (2000).
   Google Scholar
• Carlile J, Harada K, Baillie R et al Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. j Oral Pathol Med. 30(8), 449–457 (2001).
   Google Scholar
• Chan G, Boyle JO, Yang EK et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res. 59(5), 991–994 (1999).
   Google Scholar
• Nathan CA, Leskov IL, Lin M et al COX-2 expression in dysplasia of the head and neck: correlation with e1F4E. Cancer 92(7), 1888–1895 (2001).
   Google Scholar
• Blot WJ, McLaughlin JK, Winn DM et al Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 48(11), 3282–3287 (1988).
   Google Scholar
• Franceschi S, Talamini R, Ban-a S et al Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx and esophagus in northern Italy. Cancer Res. 50(20), 6502–6507 (1990).
   Google Scholar
• Negri E, La Vecchia C, Franceschi S, Tavani A. Attributable risk for oral cancer in northern Italy. Cancer Epidemiol Biomarker s Pmv. 2(3), 189–193 (1993).
   Google Scholar
• Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking and cancer of the oral cavity and oropharynx among US veterans. Cancer 72(4), 1369–1375 (1993).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (DHHS) Environmental Protection Agency. Respiaratory health effects of passive smoking: lung cancer and other disorders. In: Smoking- and tobacco control DIIf IS, USA, monograph 4(1993).
   Google Scholar
• Muscat JE, Wynder EL. Tobacco, alcohol, asbestos and occupational risk factors for laryngeal cancer. Cancer 69 (9), 2244–2251 (1992).
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Dosemeci M, Chan CC et al Occupational exposure to wood, formaldehyde and solvents and risk of nasopharyngeal carcinoma. Cancer Epidemiol Biomarker s Pmv 10(11), 1145–1153 (2001). too Spitz MR, Fueger JJ, Beddingfield NA et al Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res. 49(16), 4626–4628 (1989).
   Google Scholar
• Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. j Natl Cancer Inst. 82(22), 1773–1775 (1990).
   Google Scholar
• Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D, Hsu TC. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarker s Pmv. 2(4), 329–333 (1993).
   Google Scholar
• Spitz MR, Hogue A, Trizna Z et al Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. .1. Natl Cancer Inst. 86 (22), 1681–1684 (1994).
   Google Scholar
• Cloos J, Spitz MR, Schantz SP et al Genetic susceptibility to head and neck squamous cell carcinoma. j Natl Cancer Inst. 88(8), 530–535 (1996).
   Google Scholar
• Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. Natl Cancer Inst. 89(3), 199–211 (1997).
   Google Scholar
• Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. Natl Cancer Inst. 93(18), 1411–1418 (2001).
   Google Scholar
• Ko Y, Abel J, Harth V et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. 61(11), 4398–4404 (2001).
   Google Scholar
• Amador AG, Righi PD, Radpour S et al. Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma. Oral Sorg. Oral Med Oral Farhat. Oral Radio" Endod. 93(4), 440–445 (2002).
   Google Scholar
• Zeng J, Gong CH, Jan MG, Fun Z, Zhang LG, Li HY. Detection of Epstein-Barr virus IgA/EA antibody for diagnosis of nasopharyngeal carcinoma by immunoautoradiography. Int. j Cancer 31(5), 599–601 (1983).
   Google Scholar
• Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Eng" I Med. 333(11), 693–698 (1995). in Chien YC, Chen JY, Liu MY et al Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. Med. 345(26), 1877–1882 (2001).
   Google Scholar
• Miller WE, Cheshire JL, Baldwin AS Jr, Raab-Traub N. The NPC derived C15LMP1 protein confers enhanced activation of NF-KB and induction of the EGFR in epithelial cells. Oncogene 16(14), 1869–1877 (1998).
   Google Scholar
• Gillison ML, Koch WM, Capone RB et al Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. j Natl Cancer Inst. 92 (9), 709–720 (2000).
   Google Scholar
• Mork J, Lie AK, Glattre E et al Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. Med 344(15), 1125–1131 (2001).
   Google Scholar
• Ha PK, Pai SI, Westra WH et al Real-time quantitative PCR demonstrates low prevalence of human papillomavirus Type 16 in premalignant and malignant lesions of the oral cavity. Clin. Cancer Res. 8 (5), 1203–1209 (2002).
   Google Scholar
• Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT Human papillomavirus Type 16 and squamous cell carcinoma of the head and neck. Clin. Cancer Res. 8(10), 3187–3192 (2002).
   Google Scholar
• Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36(7Pt 2), 2699–2702 (1976).
   Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Ce//87(2), 159–170 (1996).
   Google Scholar
• Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 62(18), 5119–5125 (2002).
   Google Scholar
• OShaughnessy JA, Kelloff GJ, Gordon GB et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8(2), 314–346 (2002).
   Google Scholar
• •Presents the recent recommendations of the American Association for Cancer Research task force on the treatment and prevention of intraepithelial neoplasia.
   Google Scholar
• Lippman SM, Hong WK. Cancer prevention by delay. Commentary re: OShaughnessy JA et al, treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8(2), 305–313 (2002).
   Google Scholar
• •This commentary on the paper cited above emphasizes the value of delay as a goal of chemoprevention.
   Google Scholar
• Warren S, Gates 0. Multiple primary tumors: a survey of the literature and statistical study. Am. j Cancer 51,1358 (1932).
   Google Scholar
• Khuri FR, Kim ES, Lee JJ et al The impact of smoking status, disease stage and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarker s Prey. 10(8), 823–829 (2001).
   Google Scholar
• Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RII.Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24(2), 198–206 (2002).
   PubMed Web of Science ®Google Scholar
• Vikram B. Changing patterns of failure in head and neck cancer. Archives of Otolaryngol 110,564–565 (1984).
   PubMedGoogle Scholar
• Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer 70(1), 14–19 (1992).
   Google Scholar
• Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer75(6), 1343–1353 (1995).
   PubMed Web of Science ®Google Scholar
• Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck21(3), 204–210 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Rubin P et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. j Radiat. Oncol Biol. Phys. 17(3), 449–456 (1989).
   Google Scholar
• Schwartz LH, Ozsahin M, Zhang GN et al Synchronous and metachronous head and neck carcinomas. Cancer74(7), 1933–1938 (1994).
   PubMed Web of Science ®Google Scholar
• Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann. Otol Rhinol. Laryngol 101(2Pt 1), 105–112 (1992).
   Google Scholar
• Di Martino E, Sellhaus B, Hausmann R, Minkenberg R, Lohmann M, Esthofen MW. Survival in second primary malignancies of patients with head and neck cancer. Laryngol Otol 116(10), 831–838 (2002).
   Google Scholar
• Larson JT, Adams GL, Fattah HA. Survival statistics for multiple primaries in head and neck cancer. Otolaryngol Head Neck Surg. 103(1), 14–24 (1990).
   Google Scholar
• Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg. Oral Med Oral Pathol 46(4), 518–539 (1978).
   PubMedGoogle Scholar
• Silverman S Jr, Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg. Oral Med. Oral Pathol Oral Radial Endocl 84(2), 154–157 (1997).
   Google Scholar
• Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg. Oral Med. Oral Pathol 61(4), 373–381 (1986).
   Google Scholar
• Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer 36(4), 1386-1392 (1975).
   Google Scholar
• Mashberg A, Meyers H. Anatomical site and size of 222 early asymptomatic oral squamous cell carcinomas: a continuing prospective study of oral cancer. Cancer 37(5), 2149–2157 (1976).
   Google Scholar
• Silverman SJ, Gorsky M, Lozada E Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 53,563–568 (1984).
   PubMed Web of Science ®Google Scholar
• Bouquot JE, Weiland LH, Kurland LT Leukoplakia and carcinoma in situ synchronously associated with invasive oralioropharyngeal carcinoma in Rochester, MN, USA, 1935–1984. Oral Surg. Oral Med. Oral Pathol 65(2), 199–207 (1988).
   Google Scholar
• Lee JJ, Hong WK, Hittelman WN et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res. 6 (5), 1702–1710 (2000).
   PubMed Web of Science ®Google Scholar
• Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 36(3), 1021–1028 (1975).
   PubMed Web of Science ®Google Scholar
• Sudbo J, Sondresen JE, Reith A, Ristimaki A, Nesland JM, Byrne M. Identifying patients at high risk of oral cancer and potential treatment possibilities. Proc. Am Soc. Clin. Oncol USA (2002) (Abstract 939).
   Google Scholar
• Saito T, Sugiura C, Hirai A et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. int.,/ Oral Maxillofac. Surg. 30(1), 49–53 (2001).
   Google Scholar
• Rosin MP, Lam WL, Poh C et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 62(22), 6447–6450 (2002).
   Google Scholar
• Day GL, Blot WJ, Shore RE et al Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. j Natl Cancer Inst. 86(2), 131–137 (1994).
   Google Scholar
• Shiu MN, Chen TH, Chang SH, Hahn U. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. BE j Cancer 82(11), 1871–1874 (2000).
   Google Scholar
• Rosin MP, Cheng X, Poh C et al Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 6(2), 357–362 (2000).
   PubMed Web of Science ®Google Scholar
• Partridge M, Pateromichelakis S, Phillips E, Emilion GG, AHern RP, Langdon JD. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 60(14), 3893–3898 (2000).
   Google Scholar
• Zhang L, Epstein JB, Poh CF et al. Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas. j Oral Pathol Med. 31(3), 134–141 (2002).
   Google Scholar
• Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer 1Clin. 52(4), 195–215 (2002).
   Google Scholar
• Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int. J. Oral Maxillofac. Surg. 16(6), 656–664 (1987).
   Google Scholar
• Lydiatt WM, Anderson PE, Bazzana T et al. Molecular support for field cancerization in the head and neck. Cancer 82(7), 1376–1380 (1998).
   Google Scholar
• Thomson PJ. Field change and oral cancer: new evidence for widespread carcinogenesis? Int. j Oral Maxillofac. Surg. 31(3), 262–266 (2002).
   Google Scholar
• Lotan R. Retinoids and their receptors in modulation of differentiation, development and prevention of head and neck cancers. Anticancer Res. 16 (4C), 2415–2419 (1996).
   Google Scholar
• Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carrinogenesis 21(7), 1271–1279 (2000).
   Google Scholar
• Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 40(1), 93–101 (1988).
   PubMedGoogle Scholar
• Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl. J. Med. 348 (4), 287–294 (2003).
   Google Scholar
• Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAIVIA 287(1), 47–54 (2002).
   PubMed Web of Science ®Google Scholar
• Lippman SM, Batsakis JG, Toth BB et al Comparison of low-dose isotretinoin with I3-carotene to prevent oral carcinogenesis. N. Engl. J. Med 328(1), 15 (1993).
   Google Scholar
• Stich HF, Rosin IVfP, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with I3-carotene and with I3-carotene plus vitamin A. Int. J. Cancer 42(2), 195–199 (1988).
   Google Scholar
• Papadimitrakopoulou VA, Clayman GL, Shin DM et al Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Atrh. Otolaryngol Head Neck Surg. 125(10), 1083–1089 (1999).
   Google Scholar
• Chiesa F, Tradati N, Marazza M et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J. Cell Biochem. Suppl 17F, 255–261 (1993).
   Google Scholar
• Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J. Dent. Educ. 66(8), 896–902 (2002).
   Google Scholar
• Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Nall Cancer Inst. 86(2), 140–141 (1994).
   Google Scholar
• Bolla M, Lefur R, Ton Van J et al Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur. J. Cancer 30A(6), 767–772 (1994).
   Google Scholar
• van Zandwijk N, Dalesio 0, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Co-operative Groups. J. Nall Cancer Inst. 92 (12), 977–986 (2000).
   Google Scholar
• Mayne ST, Cartmel B, Baum M et al. Randomized trial of supplementall3-carotene to prevent second head and neck cancer. Cancer Res. 61(4), 1457–1463 (2001).
   Google Scholar
• Shin DM, Khuri FR, Murphy B et al Combined interferon-a, 13-cis-retinoic acid and a-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant Phase II trial.j Clin. Oncol 19 (12), 3010–3017 (2001).
   Google Scholar
• Lippman SM, Shin DM, Lee JJ et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res. 55 (1), 16–19 (1995).
   Google Scholar
• Shin DM, Xu XC, Lippman SM et al Accumulation of p53 protein and retinoic acid receptor-I3 in retinoid chemoprevention. Clin. Cancer Res. 3(6), 875–880 (1997).
   Google Scholar
• Sun SY, Yue P, Kelloff GJ et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl) retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Pmv 10(6), 595–601 (2001).
   Google Scholar
• Sporn MB, Suh N. Chemoprevention of cancer. Cami7ogenacis21(3), 525–530 (2000).
   Google Scholar
• Suh N, Lamph WW, Glasebrook AL et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene and a new rexinoid, LG 100268. Clin. Cancer Res. 8(10), 3270–3275 (2002).
   Google Scholar
• Suh N, Glasebrook AL, Palkowitz AD et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61(23), 8412–8415 (2001).
   Google Scholar
• Suchanek KM, May FJ, Robinson JA et al Peroxisome proliferator-activated receptor-a in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mal Catrinog. 34(4), 165–171 (2002).
   Google Scholar
• Ikawa H, Kameda H, Kamitani H et al. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp. Cell Res. 267(1), 73–80 (2001).
   Google Scholar
• Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83(3), 493–501 (1995).
   Google Scholar
• Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mc--I-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 276(52), 48997–49002 (2001).
   Google Scholar
• Yan Z, Subbaramaiah K, Camilli T et al Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-KB. J. Biol. Chem. 275(7), 4949–4955 (2000).
   Google Scholar
• Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 24(2), 96–102 (2003).
   Google Scholar
• Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med. 8(3), 289–293 (2002).
   Google Scholar
• Dannenberg AJ, Altorki NK, Boyle JO et al Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2,544–551 (2001).
   PubMed Web of Science ®Google Scholar
• Meyskens FL Jr, Gerner EW. Development of difluoromethylomithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 5(5), 945–951 (1999).
   Google Scholar
• Jacoby RF, Cole CE, Tutsch K et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas and selective toxicity against Apc mutant embryos. Cancer Res. 60(7), 1864–1870 (2000).
   Google Scholar
• D'Ambrosio SM, Gibson-D'Ambrosio R, Milo GE, Casto B, Kelloff GJ, Steele VE. Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res. 20(4), 2273–2280 (2000).
   Google Scholar
• Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG. Quantitation of chemopreventive synergism between 0-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Catrinogenesis 19(3), 419–424 (1998).
   Google Scholar
• Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 62(2), 381–385 (2002).
   PubMed Web of Science ®Google Scholar
• Li N, Chen X, Liao J et al. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA) - induced oral carcinogenesis in hamsters by tea and curcumin. Catrinogenesis 23(8), 1307–1313 (2002).
   Google Scholar
• Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21(4B), 2895–2900 (2001).
   Google Scholar
• Rocco JW, Li D, Liggett WH Jr et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin. Cancer Res. 4(7), 1697–1704 (1998).
   Google Scholar
• Nemunaitis J, Khuri F, Ganly I et al Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol 19(2), 289–298 (2001).
   Google Scholar
• Nemunaitis J, O'Brien J. Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors. Exp. Opin. Biol. Ther. 2(2), 177–185 (2002).
   Google Scholar
• Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5(7), 1715–1722 (1999).
   Google Scholar
• Reid T, Warren R, Kim D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9(12), 979–986 (2002).
   PubMedGoogle Scholar
• Koutsky LA, Ault IKA, Wheeler CM et al A controlled trial of a human papillomavirus Type 16 vaccine. N Engif Med. 347(21), 1645–1651 (2002).
   Google Scholar
• Duraiswamy J, Sherritt M, Thomson S et al Therapeutic LIVW1 polyepitope vaccine for EBV-associated Hodgkin's disease and nasopharyngeal carcinoma. Blood 101(8), 3150–3156 (2003).
   Google Scholar
• Sankaranarayanan R, Mathew B, Varghese C et al Chemoprevention of oral leukoplakia with vitamin A and I3-carotene: an assessment. Oral Oncol 33(4), 231–236 (1997).
   Google Scholar
• Epstein JB, Gorsky M, Wong FL, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 83 (4), 629–634 (1998) .
   Google Scholar
• Epstein JB, Gorsky M. Topical application of vitamin A to oral leukoplakia: a clinical case series. Cancer 86(6), 921–927 (1999).
   PubMedGoogle Scholar
• Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc. Soc. Exp. Biol. Med. 220(4), 218–224 (1999).
   Google Scholar
• Pinto H, Li Y, Kardinal C, Adams G, Pandya K. Phase III trial of low-dose 13-cis-retinoic acid for prevention of second primary cancers in Stage I-II head and neck cancer — an Eastern Co-operative Group Study. Proc. Am. Soc. Clin. Oncol (2001) (Abstract 886).
   Google Scholar